Clinical trial · Observational
Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer
A Prospective Registry Study to Evaluate Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate clinical outcomes and adverse events of salvage treatment for locoregional recurrence of breast cancer. The main questions it aims to answer are: * Clinical outcomes after salvage treatment for locoregional recurrence * Adverse events and quality of life after salvage treatment for locoregional recurrence * Patient characteristics and treatment specifics which are related to the clinical outcomes and/or adverse events * Molecular signature associated with treatment resistance Participants will be assessed by multi-dimensional methods during and after radiation therapy: * Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * Assessment for the adverse events according to CTCAE version 5.0 * Assessment for the molecular signature using residual tissue after pathologic diagnosis * Assessment for the quality of life using questionnaires (BREAST-Q)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Salvage treatment (surgery and/or radiation therapy) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Salvage treatment after locoregional recurrence
- description
- Participants who previously completed standard treatment for breast cancer and experienced locoregional recurrence alone will be undergo salvage treatment including surgery and/or radiation therapy.
- interventionNames
- Other: Salvage treatment (surgery and/or radiation therapy)
Primary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- 5 years from the initiation of the salvage therapy
- description
- The event for progression-free survival was defined as any disease progression or breast cancer-related death.
- measure
- Rate of adverse events
- timeFrame
- 5 years from the initiation of the salvage therapy
- description
- Adverse events related to the salvage therapy will be reported and incidence rate will be calculated.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients with age 18 to 100. * Previous standard definitive treatment for initial breast cancer * Locoregional recurrence without distant metastasis * Planned salvage treatment for locoregional recurrence * Informed consent of the participant Exclusion Criteria: \- Not anticipated for complying the study protocol
References
Publications (0)
Data not yet available